By David B. Miller New Scientist (US) 28 July 2017 05:33:52It may be time to look at antibiotic resistance as a new health industry and not a health industry.
That’s the conclusion of a major review of the US and UK antibiotic resistance strategies published on Tuesday.
The study was published in the journal Antimicrobial Agents and Chemotherapy, which is an industry journal.
It’s the first comprehensive review of antibiotic resistance in the United States and the UK since the World Health Organization declared the situation to be serious in the wake of a global pandemic in 2015.
It comes after US President Donald Trump ordered a review of how to combat antibiotic resistance by the end of the year.
The review concluded that both countries were making good progress on the issue, and both countries had been able to address some of the issues that prompted the US to focus on a drug-resistance strategy in the first place.
However, the authors noted that “there is still considerable uncertainty about the full impact of antibiotic-resistant infections and antibiotic resistance, as well as the impact on public health, public health-care systems, and antibiotic-resistant infections overall”.
Antibiotic resistance is one of the biggest threats facing humankind today, affecting billions of people worldwide, according to the World Food Programme.
It is a major cause of the global pandemics and the world is now facing a global shortage of antibiotics, and the US is the world’s top producer.
There is still uncertainty about what will happen in the coming year.
“It’s very clear that there is a lot of uncertainty about how the world will be able to contain and manage this global crisis,” said David J. Lutz, who chaired the review and is the director of the Center for the Study of Antimicrobials at the University of Chicago.
He also noted that the US was one of only two countries that had not implemented an effective strategy to reduce antibiotic resistance.
The authors said there was an “uncertainty around the impact of resistance on global health and public health in general”.
“This is very clear when you compare the global and US drug resistance trends, which have remained essentially unchanged,” they said.
The authors of the study pointed out that while some of their recommendations focused on improving antibiotic use, they didn’t include an outright ban on antibiotic use for routine healthcare.
Instead, they recommended more collaboration and shared information to find ways to make antibiotics more available to patients, and to work together to develop better ways to fight the spread of antibiotic resistant infections.
This could include collaborating on development of new drug delivery systems, as proposed by the US Department of Defense.
But this could also include more public-private partnerships, including developing new drugs, and increasing access to antibiotics, they said in their report.
In the meantime, they suggested that both governments should look at ways to develop a global drug resistance strategy, which they said would be a “positive first step” towards addressing antibiotic resistance across the globe.
There are also important gaps in the global resistance strategy that can be addressed by both countries, such as how to use different drug classes to fight resistance and whether there should be an international approach to tackling antibiotic resistance and its impact on the public health system, the researchers wrote.